Truist lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $18 from $21 but keeps a Buy rating on the shares after its Q4 results and guidance. The company’s FY25 revenues are expected to be $75-$90M, which is about 30% below midpoint of consensus of $105M, and given the increased competition in the neuroblastoma space for patients, Truist is adjusting Danyelza revenues to reflect a more gradual ramp, the analyst tells investors in a research note. The firm adds however that despite the pull back in recent weeks, there is more upside for the stock and high value expected from the company’s radioimmunotherapy platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics price target lowered to $7 from $11 at Morgan Stanley
- Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer
- Positive Growth Prospects and Strategic Developments Drive Buy Rating for Y-Mabs Therapeutics
- Y-mAbs Therapeutics Reports 2024 Financial Results
- Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results